Data Science  Â·  Machine Learning  Â·  Drug Discovery

Komla Gnona, PhD

Data Scientist & Drug Discovery Scientist

I build statistical and machine-learning models on large, messy biological and clinical data, then turn what they find into decisions: which compound to advance, which patient is at risk, which signal is real. Ten-plus years across drug discovery, genomics, and applied ML, with a patent and peer-reviewed work behind it.

Grounded in statistics, applied across the stack

My PhD at Ohio State was in statistical genetics: small-sample and rare-event inference, work that ended up peer-reviewed in the American Journal of Epidemiology. That grounding shows up in everything since. I build models that are accurate, but also honest about their own uncertainty.

Since then I've worked across predictive modeling, biomarker analysis, and ML pipeline development in drug discovery: a Senior Scientist role at Amgen, data science and computational biology at Sensorium Therapeutics, and a research fellowship in HIV genomics.

I care about the unglamorous parts: reproducible pipelines, honest evaluation on imbalanced data, and code a colleague can read six months later. I work best sitting between the bench scientists and the cluster, translating what came out of an experiment into something a team can act on.

Education
PhD, Computational Biology (Statistical Genetics), The Ohio State University, 2022 Mathematics Genealogy Project
BS, Mathematics, The Ohio State University, 2015
Patent
WO2021061697A1, neonatal complication prediction, via Nationwide Children's Hospital
Publications
Gnona KM, et al. Revisiting the Wald Test in Small Case-Control Studies. American Journal of Epidemiology, 2022
Stewart WCL, Gnona KM, et al. Genetic Prediction of Neonatal Complications Using Exome-Wide Variation. Pediatric Research, 2020

Where I've applied it

  1. Apr 2025 to May 2026

    Senior Scientist, Biomarker Analysis

    Amgen

    • Led biomarker analysis for clinical programs including rocatinilimab (AMG 451) and efavaleukin alfa (AMG 592), using linear mixed models against statistical analysis plans to support translational and mechanistic interpretation.
    • Integrated multi-omics and clinical datasets to identify mechanistic drivers of immune-mediated disease.
    • Built and benchmarked predictive ML models on high-dimensional data with rigorous validation and error-mode analysis.
    • Communicated technical findings to clinical, translational, and discovery stakeholders.
  2. Sep 2024 to Apr 2025

    R&D Scientist II, Computational Biology & Data Science

    Sensorium Therapeutics

    • Analyzed large-scale multi-conditional single-cell RNA-seq and perturbation-screen data on iPSC-derived human neuronal models to drive discovery decisions.
    • Built ML and statistical models classifying compound mechanisms of action from single-cell and phenotypic readouts; the work fed prioritization decisions on a program now in Phase 1 clinical trials.
    • Built scalable Nextflow pipelines on AWS and Slurm HPC for terabyte-scale single-cell and multi-omics datasets.
    • Co-wrote and helped secure SBIR Phase I research funding.
  3. Sep 2022 to Sep 2024

    R&D Scientist I, Computational Biology

    Sensorium Therapeutics

    • Developed and optimized bioinformatics workflows for bulk, single-cell, and spatial transcriptomics.
    • Ran integrative multi-omics analyses across gene expression, phenotype, and functional readouts.
    • Improved data reliability through normalization, batch-effect correction, and feature engineering.
  4. Mar 2022 to Aug 2022

    Research Fellow, HIV Genomics

    Henry M. Jackson Foundation

    • Built NGS pipelines for viral and host genomic sequence data; applied statistical and survival models to identify mutation-driven patterns.
    • Conducted sequence homology (BLAST, HMMER) and phylogenomic analyses for mutation-impact assessment.
  5. Aug 2016 to Mar 2022

    Graduate Research Associate, PhD in Computational Biology

    The Ohio State University

    • Built statistical and computational frameworks for GWAS, variant calling, and predictive risk stratification on large-scale sequencing cohorts.
    • Developed novel statistical-testing methodology for case-control studies, peer-reviewed in the American Journal of Epidemiology.
    • Managed HPC infrastructure (Slurm, SGE) for terabyte-scale parallel computation.

Models built to hold up under scrutiny

Each of these started as a modeling question and ended as a number I'm willing to defend, including the corrections that made the number smaller.

Neonatal complication risk prediction

87%

AUC, corrected

Polygenic risk score from 182 sequenced exomes in preterm infants (26–31 weeks), combined with gestational age. Raw AUC of 96% dropped to 87% once I corrected for over-fitting. That is the honest number, and the one that matters. Published in Pediatric Research.

  • Genomics
  • PRS
  • Exome sequencing

Mechanism-of-action classifier

760

MoA classes

Random-forest model classifying compounds into 760 distinct mechanism-of-action classes from L1000 gene-expression signatures, at over 80% accuracy. Built to give chemists a first read on what a new compound is probably doing.

  • L1000
  • Random Forest
  • scikit-learn

Blood-brain-barrier permeability model

0.96

AUC

Random-forest classifier predicting BBB permeability from compound features, built to prioritize candidates earlier in the discovery pipeline. The features that carry the model (logP, molecular weight, TPSA) are exactly the ones medicinal chemists already reason about, which is what made it trustworthy to them.

  • RDKit
  • Random Forest
  • Drug discovery

Perturb-seq screens ranked by E-distance

~10%

true KO rate

CRISPR screen analysis with pertpy: Mixscape to separate true knockouts from escapers, where only about one cell in ten was really perturbed, then E-distance to rank effect size and an E-test for significance. Top hits recover the IFN-γ/JAK-STAT axis with correct STAT1 specificity, plus a genetic-interaction table calling synergy vs. suppression in double perturbations.

  • pertpy
  • scanpy
  • Mixscape
  • E-distance

Single-cell integration & label transfer

98%

cell-type accuracy

Benchmarked PCA vs. Harmony vs. scVI on the heart cell atlas using batch-mixing entropy and cell-type silhouette. Harmony wins on mixing, scVI preserves more biology, and both beat raw PCA. A genuine trade-off rather than a winner. Then scANVI for label transfer, reaching 98% on held-out cells, with errors concentrated in rare and similar types.

  • scvi-tools
  • PyTorch
  • Harmony
  • scANVI

AlphaMissense benchmarked against ClinVar

0.944

ROC-AUC

Scored AlphaMissense pathogenicity predictions against ClinVar labels across ten disease genes. The headline AUC is strong, but the interesting result is the failure mode: NPC1 I1061T, a common and firmly pathogenic Niemann-Pick C1 mutation, scores 0.303 and is called benign. Aggregate metrics hide the misses that matter clinically.

  • ClinVar
  • MyVariant.info
  • ROC analysis

Flow-cytometry gate classification

~90%

accuracy

ResNet transfer-learning model for binary gate classification, fine-tuned with early layers frozen to adapt a general-purpose image model to flow-cytometry data. A practical way to get a useful classifier out of a small labelled set.

  • ResNet
  • Transfer learning
  • PyTorch

RAG over the drug literature

2×

eval tiers

Retrieval-augmented QA over real PubMed abstracts, with cited answers and a hallucination guard that refuses when the retrieved context doesn't support a claim. Evaluated in two tiers. Recall@k and MRR for the retriever, then LLM-as-judge faithfulness and answer relevancy for the generator, because a good retriever and a good answer are different failures.

  • RAG
  • DeepEval
  • LLM-as-judge
  • PubMed API

The toolkit

Statistics & modeling

  • Linear & generalized mixed models
  • Regularized regression
  • High-dimensional hypothesis testing
  • Survival analysis
  • Over-fitting correction & validation
  • Statistical method development

Machine learning & AI

  • scikit-learn, random forests
  • PyTorch, TensorFlow
  • CNNs & transfer learning
  • Imbalanced-data evaluation
  • RAG & LLM evaluation
  • ML pipeline development

Genomics & omics

  • Single-cell RNA-seq (Scanpy, Seurat)
  • Perturb-seq & CRISPR screens
  • Bulk & spatial transcriptomics
  • GWAS & variant interpretation
  • Proteomics (LFQ, TMT, SILAC)
  • Multimodal data integration

Data & infrastructure

  • Python (pandas, NumPy, SciPy)
  • R (tidyverse, Bioconductor)
  • SQL & shell
  • Nextflow
  • Slurm / SGE on Linux HPC
  • AWS (S3, EC2, Batch), GCP